CO5631442A2 - Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
CO5631442A2
CO5631442A2 CO04098197A CO04098197A CO5631442A2 CO 5631442 A2 CO5631442 A2 CO 5631442A2 CO 04098197 A CO04098197 A CO 04098197A CO 04098197 A CO04098197 A CO 04098197A CO 5631442 A2 CO5631442 A2 CO 5631442A2
Authority
CO
Colombia
Prior art keywords
alk
radical
carbon atoms
fgfs
inhibitors
Prior art date
Application number
CO04098197A
Other languages
English (en)
Inventor
Alain Bardoc
Francoise Bono
Marie Francoise Bordes
Nathalie Guillo
Herbert Jean-Marc
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of CO5631442A2 publication Critical patent/CO5631442A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1.- Compuestos de fórmula I, en la cual - R1 representa un radical hidroxi, un radical alcoxi lineal o ramificado de 1 a 5 átomos de carbono, un radical carboxi, un radical alcoxicarbonilo de 2 a 6 átomos de carbono o un radical de fórmula:-NR5R6 -NH-SO2-Alk-NH-SO2-Ph -NH-CO-Ph-N (Alk) -CO- Ph-NH-CO-NH-Ph -NH-CO-Alk-NH-CO2-Alk-O-(CH2)n-cAlk-O-Alk-COOR7-O-Alk-O-R8-O-Alk-OH -O-Alk-C(NH2) : NOH -O-Alk-NR5R6-O-Alk-CN -O-(CH2)n-Ph-O-Alk-CO-NR5R6-CO-NH-(CH2)m-COOR7-CO-NH-Alk en las cuales Alk representa un radical alquilo o un radical alquileno lineal o ramificado de 1 a 5 átomos de carbono,cAlk representa un radical cicloalquilo de 3 a 6 átomos de carbono, n representa un número entero de 0 a 5, m representa un número entero de 1 a 5, R5 y R6 idénticos o diferentes representan, cada uno, un átomo de hidrógeno, un radical alquilo lineal o ramificado de 1 a 5 átomos de carbono o un radical bencilo, R7 representa un átomo de hidrógeno o un radical alquilo de 1 a 5 átomos de carbono,R9 representa un radical alquilo de 1 a 5 átomos de carbono o un radical -CO-Alk,Ph representa un radical fenilo eventualmente substituido por uno o varios átomos de halógeno,por uno o varios radicales alcoxi de 1 a 5 átomos de carbono, por uno o varios radicales carboxi o ...
CO04098197A 2002-04-04 2004-10-01 Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen CO5631442A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0204220A FR2838123B1 (fr) 2002-04-04 2002-04-04 Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf

Publications (1)

Publication Number Publication Date
CO5631442A2 true CO5631442A2 (es) 2006-04-28

Family

ID=28052118

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04098197A CO5631442A2 (es) 2002-04-04 2004-10-01 Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (34)

Country Link
US (2) US7442708B2 (es)
EP (1) EP1495023B1 (es)
JP (1) JP4741799B2 (es)
KR (1) KR101022138B1 (es)
CN (1) CN100413863C (es)
AR (1) AR040404A1 (es)
AT (1) ATE304013T1 (es)
AU (1) AU2003240984B2 (es)
BR (1) BR0309026A (es)
CA (1) CA2476056C (es)
CO (1) CO5631442A2 (es)
DE (1) DE60301570T2 (es)
DK (1) DK1495023T3 (es)
EA (1) EA007902B1 (es)
EC (1) ECSP045338A (es)
ES (1) ES2247540T3 (es)
FR (1) FR2838123B1 (es)
HK (1) HK1074631A1 (es)
HR (1) HRP20040912B1 (es)
IL (2) IL163755A0 (es)
IS (1) IS2475B (es)
MA (1) MA27297A1 (es)
ME (2) ME00118B (es)
MX (1) MXPA04009639A (es)
NO (1) NO329025B1 (es)
NZ (1) NZ534786A (es)
PL (1) PL215265B1 (es)
RS (1) RS51399B (es)
SI (1) SI1495023T1 (es)
TN (1) TNSN04188A1 (es)
TW (1) TWI335222B (es)
UA (1) UA78016C2 (es)
WO (1) WO2003084956A1 (es)
ZA (1) ZA200406613B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
AU2005257107A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
EP1819338A4 (en) * 2004-11-22 2009-11-04 Threshold Pharmaceuticals Inc ANTICANCER TUBULIN-BINDING AGENTS AND THEIR PRODUCTS
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
EP2331541B1 (en) * 2008-09-04 2015-04-22 Boehringer Ingelheim International GmbH Indolizine inhibitors of leukotriene production
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
EP2270043A1 (en) * 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
CN101648953B (zh) * 2009-09-24 2012-09-05 绍兴文理学院 一种咪唑并[1,2-b]吡咯并[1,2-f]哒嗪衍生物及其制备方法和用途
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2967412B1 (fr) * 2010-11-17 2012-12-14 Sanofi Aventis Nouveaux derives d'indolizine, leur preparation et leur application en therapeutique
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
BR112017012146B1 (pt) * 2014-12-10 2023-11-21 Ono Pharmaceutical Co., Ltd Composto derivado de di-hidroindolizinona, seu uso, composição farmacêutica e inibidor de fxia
EP3318563A1 (en) * 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
CN108864083B (zh) * 2018-06-07 2021-05-25 广东药科大学 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物
CN110251513A (zh) * 2019-07-03 2019-09-20 南京大学 一种含吡唑的中氮茚化合物在制备抗肿瘤药物中的应用
US11976066B1 (en) 2023-10-23 2024-05-07 King Faisal University Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
US4378362A (en) * 1979-12-06 1983-03-29 S.A. Labaz N.V. Indolizine derivatives and process for preparing the same
FR2528845A1 (fr) * 1982-06-17 1983-12-23 Sanofi Sa Nouveaux derives d'indolizine, leur procede de preparation ainsi que les compositions therapeutiques les contenant
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB9318790D0 (en) * 1993-09-10 1993-10-27 Fujisawa Pharmaceutical Co Heterocyclic derivatives
TR200103352T2 (tr) * 1999-05-21 2005-03-21 Bristol-Myers Squibb Company Kinas pirolotriazin inhibitörleri
WO2002098876A1 (en) * 2001-06-06 2002-12-12 Vertex Pharmaceuticals Incorporated Cak inhibitors and uses thereof
FR2859997B1 (fr) * 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
ZA200406613B (en) 2007-12-27
HRP20040912A2 (en) 2004-12-31
KR20040099388A (ko) 2004-11-26
US20090023770A1 (en) 2009-01-22
ME00118B (me) 2010-10-10
US20050203126A1 (en) 2005-09-15
NZ534786A (en) 2006-06-30
CA2476056A1 (fr) 2003-10-16
KR101022138B1 (ko) 2011-03-17
IL163755A0 (en) 2005-12-18
EA200400994A1 (ru) 2005-06-30
FR2838123A1 (fr) 2003-10-10
ECSP045338A (es) 2005-03-10
TW200306181A (en) 2003-11-16
CN1649867A (zh) 2005-08-03
AU2003240984B2 (en) 2008-07-31
ES2247540T3 (es) 2006-03-01
TWI335222B (en) 2011-01-01
AU2003240984A1 (en) 2003-10-20
EP1495023B1 (fr) 2005-09-07
UA78016C2 (uk) 2007-02-15
JP2005532286A (ja) 2005-10-27
MEP22508A (en) 2010-06-10
CA2476056C (fr) 2012-03-06
EP1495023A1 (fr) 2005-01-12
TNSN04188A1 (fr) 2007-03-12
DE60301570T2 (de) 2006-05-18
ATE304013T1 (de) 2005-09-15
DK1495023T3 (da) 2005-12-27
PL215265B1 (pl) 2013-11-29
MA27297A1 (fr) 2005-05-02
JP4741799B2 (ja) 2011-08-10
IS2475B (is) 2008-12-15
SI1495023T1 (sl) 2005-12-31
HRP20040912B1 (hr) 2012-10-31
BR0309026A (pt) 2005-02-09
DE60301570D1 (de) 2005-10-13
WO2003084956A1 (fr) 2003-10-16
NO329025B1 (no) 2010-08-02
US7442708B2 (en) 2008-10-28
HK1074631A1 (en) 2005-11-18
AR040404A1 (es) 2005-04-06
MXPA04009639A (es) 2005-07-13
EA007902B1 (ru) 2007-02-27
FR2838123B1 (fr) 2005-06-10
RS51399B (en) 2011-02-28
IS7413A (is) 2004-08-19
US7803811B2 (en) 2010-09-28
CN100413863C (zh) 2008-08-27
PL372812A1 (en) 2005-08-08
RS86404A (en) 2006-12-15
NO20044156L (no) 2005-01-03
IL163755A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CO5631442A2 (es) Nuevos derivados de indolizina 1,2,3 sustituida, inhibidores de los fgfs, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR055053A1 (es) Compuestos indol sustituidos con actividad inhibidora de nos. composiciones farmaceuticas.
CO5560575A2 (es) Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen
DE602007007065D1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
ECSP066976A (es) 4-fenilamino-quinazolin-6-il-amidas
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
SE0202133D0 (sv) Novel compounds
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
NO20053647L (no) Pyrazolopyridinderivater
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
ATE338461T1 (de) Pyrazolpyrimidinfungizide
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
ECSP077270A (es) Ácidos de tiazolo - naftilo
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
ATE478054T1 (de) Benzimidazolderivate
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MX9806246A (es) PIPERIDINAS NOVEDOSAS DERIVADAS DE 1-/(PIPERAZIN-1-IL)ARIL-(OXI/AMINO)CARBONIL(4-ARIL-PIPERIDIN A COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR 5-HT-1D- beta-.

Legal Events

Date Code Title Description
FC Application refused
FG Application granted
FD Application lapsed